Companies / IVX

INVION LIMITED

ASX:IVXPharmaceuticals, Biotechnology & Life Sciences
109.2M shares on issueASX (delayed) · as of 28 July 2026$0.046price · delayed$4.9Mmarket cap · indicative
NR
Dilution grade

Not rated — share-count series unreliable

Cash runway-0.7 quarters of funding
Share-count growth (24m)no data — share-count series unreliable
Raise cadence (24m)5 cash raisesexcludes announced events with no matching share-issuance (Appendix 2A) filing
Options & rights overhang36.9% of sharesconsolidation-adjusted
In-the-money supply0.0% of sharesconsolidation-adjusted
Pending proposed issuesnone

INVION LIMITED's share-count series is marked "share-count series unreliable" and it completed an approximately 1-for-6.1 share consolidation on November 2024; the reported latest share count is 109M as of June 2026 (consolidation-adjusted). The company raised capital five times in the 24-month window for total proceeds of A$6.5M, most recently A$1.2M via convertible notes in January 2026. Options and rights could convert into 40M new shares, equal to 36.9% of the current share count, with 0% in the money and the nearest expiry in November 2026; these figures are consolidation-adjusted. At the March 2026 quarter the company reported A$-468K in cash, covering -0.7 quarters. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
36.9%
Max option dilution
0.0%
ITM option dilution
2
Raises · last 12 months
-0.7 qtrs
Cash cover · under 2 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Adjusted for the 1-for-6.1 consolidation (27 Nov 2024). Latest count 109.2M per ASX (delayed) (28 July 2026).
77.2M89.0M100.7MDec 24Sept 25July 26Cash raise · 28 Jan 2026Cash raise · 28 Jan 2026Cash raise · 20 June 2025Cash raise · 12 June 2025Cash raise · 27 Feb 2025

Cash runway

-0.7 qtrs
Less than two quarters of funding at the recent spend rate — near-term funding pressure.
$-468k available cash at quarter ended 31 Mar 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 31 Mar 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
22 June 20262A · quoted issueIVX : ORDINARY FULLY PAID109.2MAppendix 2A
22 June 20263G · unquotedIVX : ORDINARY FULLY PAID109.2MAppendix 3G
16 June 20263G · unquotedORDINARY FULLY PAID109.2MAppendix 3G
12 June 20263G · unquotedIVX : ORDINARY FULLY PAID97.0MAppendix 3G
12 June 20262A · quoted issueIVX : ORDINARY FULLY PAID12.2MAppendix 2A
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

5 cash raises in the last 24 months · 2 in the last 12 months

$1.3M
Convertible Notes
28 Jan 2026 ACTIVE
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

consolidation-adjusted Figures rebased for the share consolidation in the last 24 months.

36.9%
Total overhang · of current shares
0.0%
In the money · at current price
40.3M
Potential new shares
Nov 2026
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
12 June 2026Alistair BennallackOther—1.7M—3Y notice
12 June 2026Chiat Thian ChewOther—4.8M—3Y notice
12 June 2026Alan YamashitaOther—1.7M—3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

22 June 2026Notification regarding unquoted securities - IVX
22 June 2026Application for quotation of securities - IVX
21 June 2026Global PDT Leader Dr Colin Hopper Appointed Clinical Advisor
19 June 2026Change of Directors' Interest Notices x 3
16 June 2026Notification regarding unquoted securities - IVX
12 June 2026Notification regarding unquoted securities - IVX
12 June 2026Notification regarding unquoted securities - IVX
12 June 2026Notification regarding unquoted securities - IVX
12 June 2026Application for quotation of securities - IVX
29 May 2026Results of Extraordinary General Meeting
18 May 2026$PPhotosoft Platform Expands to Eye Diseases Via Partnership
11 May 2026Correction to Appendix 3Y - Alistair Bennallack
1 May 2026Notification of cessation of securities - IVX
30 Apr 2026$PAppendix 4C and Quarterly Activities Report - March 2026
28 Apr 2026Notice of General Meeting/Proxy Form
21 Apr 2026Bionnova 2026 Investor Presentation
20 Apr 2026$PSkin Cancer Trial Moves to BCC With More Encouraging Signals
20 Apr 2026Appendix 3Y Clarification
20 Apr 2026Change of Director's Interest Notice - Thian Chew
8 Apr 2026Change of Substantial Holding

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.